Who is sponsoring COSPAR II?

COSPAR II is sponsored by UCB Pharma.

What condition does COSPAR II study?

COSPAR II studies Crohn's Disease.

What drugs are being tested in COSPAR II?

Interventions: Certolizumab pegol.

What is the status of COSPAR II?

COSPAR II is currently COMPLETED.

Last reviewed 2018-07-10 · How we verify

An Open-label, Multi-center Trial to Examine the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease Previously Enrolled in C87059 (COSPAR I, NCT00349752). (COSPAR II)

NCT00356408 Phase 3 COMPLETED Results posted

This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol (CDP870) in patients with moderate to severe Crohn's disease previously enrolled in C87059 (COSPAR I, NCT00349752).

Details

Lead sponsor	UCB Pharma
Phase	Phase 3
Status	COMPLETED
Enrolment	106
Start date	2007-01
Completion	2010-02

Conditions

Crohn's Disease

Interventions

Certolizumab pegol

Primary outcomes

Occurrence of at Least One Treatment-emergent Adverse Event During This Study (Maximum 122 Weeks) — During this study (maximum 122 weeks)
Results are presented as the number of subjects with at least one treatment-emergent adverse event during this study.

Countries

United States, Canada, Germany